Samuel Blackman

Dr. Samuel Blackman is a scientific advisor at Notable Labs. Samuel has over 10 years of experience in the biotech industry, with a focus on oncology drug development. Prior to joining Notable Labs, they served as head of clinical development at Mavupharma, Inc., where they were responsible for devising the clinical development strategy and planning towards an IND for their lead compound, MV-104. Mavupharma was acquired by Abbvie in July 2019.

Previously, Dr. Blackman was senior vice president and head of clinical development at Silverback Therapeutics. In this role, they were responsible for leading Silverback's clinical development efforts. Prior to Silverback, they served as senior medical director at Juno Therapeutics, where they provided clinical leadership for the CD19 CAR T cell program for B cell malignancies.

Before Juno, Dr. Blackman was executive director and head of translational medicine at Seattle Genetics. In this role, they were responsible for leading Seattle Genetics' translational medicine efforts. Prior to Seattle Genetics, they served as director of oncology early clinical development at GlaxoSmithKline.

Dr. Blackman received their MD from Harvard Medical School and their MBA from Stanford Graduate School of Business. Samuel completed their residency in internal medicine at Massachusetts General Hospital and their fellowship in medical oncology at Dana-Farber Cancer Institute.

Dr. Blackman received their MD from the University of Illinois College of Medicine and their PhD in Pharmacology from the University of Illinois Chicago. Samuel also holds a BA in Philosophy from the University of Chicago. Samuel is board certified by the American Board of Pediatrics in both Pediatrics and Neonatal-Perinatal Medicine.